• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

APhA Foundation Announces Recipients of the Incentive Grants Focused on Serving Patients With Alzheimer's Disease and Dementia

Posted on: Friday, 15 July 2005, 12:00 CDT

WASHINGTON, July 15 /PRNewswire/ -- The American Pharmacists Association (APhA) Foundation announces five recipients to receive incentive grants for projects that focus on serving patients with Alzheimer's disease and dementia. The five pharmacists are awarded $1,000 to initiate a 12-month innovative practice project or to support an already existing project. These five incentive grants are supported by Eisai Inc.

The recipients and their project titles are: * Nicole Jennifer Brandt, Pharm.D., CGP, BCPP, University of Maryland School of Pharmacy, Baltimore, MD, Project Title: Improving the Care of Individuals with Dementia in a Managed Care Organization; * Heather Allison Greene, Pharm.D., Co-Investigators: Patricia Slattum, Pharm.D., Ph.D., Edward Shibley, R.Ph., MBA, Plaza Professional Pharmacy, Richmond, VA, Project Title: Cognitive Health Awareness Program; * Ly Lguyen, Pharm.D., Ralph's Pharmacy, Compton, CA, Project Title: Increasing Alzheimer's disease awareness through memory loss screenings and patient education; * Stephen M. Setter, Pharm.D.; Visiting Nurse Association Home Healthcare Service, Spokane, WA, Project Title: Detecting Cognitive Impairment in Home Bound Community Dwelling Older Adults Using the Mini-Cog: A Rapid Screening Tool for Dementia; * Mandy Wilson, Pharm.D., CDM, Sandy Springs Pharmacy, Atlanta, GA, Project Title: Community Pharmacy Mild Cognitive Impairment Program - Development and evaluation of a mild cognitive impairment screening, education and medication therapy management service.

The APhA Foundation Incentive Grants program is intended to focus pharmacists' attention on the need to re-engineer their practices along lines that incorporate more specific patient-centered services and enhance health care delivery. Criteria for project proposals for the Incentive Grants focusing on serving patients with Alzheimer's disease and dementia were to include one or all of the following:

* Improve identification of patients who may have Alzheimer's disease for referral to physicians for complete assessment, diagnosis and treatment. * Establish an Alzheimer's disease monitoring practice model in ambulatory care practice settings that improves patient care and treatment. The project can include screening, wellness and support services in an effort to address the spectrum of patient and provider needs. * Establish effective monitoring, management and feedback processes within the collaborative treatment of Alzheimer's patients and utilize the pharmacist-physician interaction to optimize therapeutic treatment. * Demonstrate that screening and disease management services enable patients to be more informed, involved, and in control of their health resulting in improved persistence and compliance with therapy. * Implement community education and awareness programs in partnership with the local Alzheimer's Association or other patient advocacy groups. * Establish services that provide medication management support for patients with Alzheimer's diseases and dementia and their caregivers.

The APhA Foundation has been awarding incentive grants to pharmacists for more than ten years. The program was established to provide pharmacists with $1,000 in seed money to implement an innovative pharmaceutical care project within their pharmacy practice or to expand an already existing project. For more information about the Incentive Grants program visit the APhA Foundation's web site at: http://www.aphafoundation.org/ and click onto Incentive Grants.

The APhA Foundation is affiliated with the American Pharmacists Association. The APhA Foundation, a nonprofit organization based in Washington, DC, works to design solutions to medication use problems in America. The APhA Foundation's mission is to improve consumer health outcomes that are affected by pharmacy.

Eisai Inc. is a US pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products in more than 30 countries. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of approximately $2 billion in fiscal year 2004 (year ended March 31, 2005).

Eisai Inc. employs approximately 1,200 people at its headquarters in Teaneck, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. Between 1998 and 2004, Eisai Inc. moved up rapidly in the rankings (based on revenues) of US pharmaceutical companies from No. 44 to No. 19.

American Pharmacists Association Foundation

CONTACT: Sandra Kimble of American Pharmacists Association,+1-202-429-7537, or SKimble@aphanet.org

Web site: http://www.aphafoundation.org/

Source: PRNewswire

More News in this Category